Page 2 - Dirk Neum News Today

EQS-News: Biotest AG / Key word(s): StudyBiotest expands its clinical development program for trimodulin to patients with community-acquired pneumonia (CAP) 12.12.2023 / 09:00 CET/CESTThe issuer is solely responsible for the content of this announcement. PRESS RELEASE    Biotest expands its clinical d...

EQS-News: Biotest AG / Key word: 9 Month figures Biotest increases EBIT to Euro 125.4 million in the first nine months of 2023 02.11.2023 / 08:00 CET/CEST The issuer...

EQSAdhoc Biotest AG Key word Change in Forecast Biotest AG Increase of the EBIT guidance 05Oct2023 1655 CETCEST Disclosure of an inside information acc to Article 17 MAR of the Regulation No 5962014

EQS-Ad-hoc: Biotest AG / Key word: Personnel Biotest AG: Peter Janssen appointed new Chairman of the Board of Biotest AG 05-Oct-2023 / 16:42 CET/CEST Disclosure of an inside...

EQS-Ad-hoc: Biotest AG / Key word: Change in Forecast Biotest AG: Increase of the EBIT guidance 05-Oct-2023 / 16:55 CET/CEST Disclosure of an inside information acc. to...

EQSAdhoc Biotest AG Key word Personnel Biotest AG Peter Janssen appointed new Chairman of the Board of Biotest AG 05Oct2023 1642 CETCEST Disclosure of an inside information acc to Article 17 MAR of t

EQS-Ad-hoc: Biotest AG / Key word(s): Change in Forecast Biotest AG: Increase of the EBIT guidance 05-Oct-2023 / 16:55 CET/CEST ...

EQS-News: Biotest AG / Key word: Regulatory Approval Biotest AG: Biotest receives approval for innovative immunoglobulin Yimmugo® in the UK 21.09.2023 / 09:00...

EQS-News: Biotest AG / Key word: Study Biotest AG: Biotest treats first patient with severe community-acquired pneumonia in phase III trial with trimodulin...

EQS-News: Biotest AG / Key word: Regulatory Admission Biotest AG: US Food and Drug Administration FDA accepts marketing authorization application for immunoglobulin...